These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 26563369)
1. Involvement of Numb-mediated HIF-1α inhibition in anti-proliferative effect of PNA-antimiR-182 in trastuzumab-sensitive and -resistant SKBR3 cells. Sajadimajd S; Yazdanparast R; Akram S Tumour Biol; 2016 Apr; 37(4):5413-26. PubMed ID: 26563369 [TBL] [Abstract][Full Text] [Related]
2. Sensitizing effect of juglone is mediated by down regulation of Notch1 signaling pathway in trastuzumab-resistant SKBR3 cells. Sajadimajd S; Yazdanparast R Apoptosis; 2017 Jan; 22(1):135-144. PubMed ID: 27770268 [TBL] [Abstract][Full Text] [Related]
3. Differential behaviors of trastuzumab-sensitive and -resistant SKBR3 cells treated with menadione reveal the involvement of Notch1/Akt/FOXO1 signaling elements. Sajadimajd S; Yazdanparast R Mol Cell Biochem; 2015 Oct; 408(1-2):89-102. PubMed ID: 26116017 [TBL] [Abstract][Full Text] [Related]
4. Activation of STAT3/HIF-1α/Hes-1 axis promotes trastuzumab resistance in HER2-overexpressing breast cancer cells via down-regulation of PTEN. Aghazadeh S; Yazdanparast R Biochim Biophys Acta Gen Subj; 2017 Aug; 1861(8):1970-1980. PubMed ID: 28499822 [TBL] [Abstract][Full Text] [Related]
5. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells. Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856 [TBL] [Abstract][Full Text] [Related]
6. Mycophenolic acid potentiates HER2-overexpressing SKBR3 breast cancer cell line to induce apoptosis: involvement of AKT/FOXO1 and JAK2/STAT3 pathways. Aghazadeh S; Yazdanparast R Apoptosis; 2016 Nov; 21(11):1302-1314. PubMed ID: 27651367 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. Vazquez-Martin A; Colomer R; Brunet J; Menendez JA Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307 [TBL] [Abstract][Full Text] [Related]
8. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer. Kazi AA; Gilani RA; Schech AJ; Chumsri S; Sabnis G; Shah P; Goloubeva O; Kronsberg S; Brodie AH Breast Cancer Res; 2014 Jan; 16(1):R15. PubMed ID: 24472707 [TBL] [Abstract][Full Text] [Related]
9. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855 [TBL] [Abstract][Full Text] [Related]
10. Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells. Zhao Y; Wang Z; Jiang Y; Yang C Cancer Lett; 2011 Dec; 313(1):54-63. PubMed ID: 21943825 [TBL] [Abstract][Full Text] [Related]
11. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935 [TBL] [Abstract][Full Text] [Related]
12. miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer. Tang H; Song C; Ye F; Gao G; Ou X; Zhang L; Xie X; Xie X J Cell Mol Med; 2019 Dec; 23(12):8114-8127. PubMed ID: 31599500 [TBL] [Abstract][Full Text] [Related]
13. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. Gong C; Yao Y; Wang Y; Liu B; Wu W; Chen J; Su F; Yao H; Song E J Biol Chem; 2011 May; 286(21):19127-37. PubMed ID: 21471222 [TBL] [Abstract][Full Text] [Related]
14. MiRNA‑542‑3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation. Ma T; Yang L; Zhang J Oncol Rep; 2015 Mar; 33(3):1215-20. PubMed ID: 25586125 [TBL] [Abstract][Full Text] [Related]
15. microRNA-216b enhances cisplatin-induced apoptosis in osteosarcoma MG63 and SaOS-2 cells by binding to JMJD2C and regulating the HIF1α/HES1 signaling axis. Yang D; Xu T; Fan L; Liu K; Li G J Exp Clin Cancer Res; 2020 Sep; 39(1):201. PubMed ID: 32972441 [TBL] [Abstract][Full Text] [Related]
16. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802 [TBL] [Abstract][Full Text] [Related]
17. MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Δ16 mediated breast tumorigenesis and reverse trastuzumab resistance. Huynh FC; Jones FE PLoS One; 2014; 9(12):e114419. PubMed ID: 25532106 [TBL] [Abstract][Full Text] [Related]
18. NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells. Yang L; Li Y; Shen E; Cao F; Li L; Li X; Wang X; Kariminia S; Chang B; Li H; Li Q Int J Oncol; 2017 Nov; 51(5):1553-1562. PubMed ID: 29048656 [TBL] [Abstract][Full Text] [Related]
19. Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer. Le XF; Almeida MI; Mao W; Spizzo R; Rossi S; Nicoloso MS; Zhang S; Wu Y; Calin GA; Bast RC PLoS One; 2012; 7(7):e41170. PubMed ID: 22829924 [TBL] [Abstract][Full Text] [Related]
20. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer. Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]